Eczema (Atopic Dermatitis) Clinical Trials in Seattle

View 16 new treatments for Eczema (Atopic Dermatitis) in Seattle, WA, and other areas near me, such as Bellevue, Everett, Kent and Renton. Every day, Power helps hundreds of eczema patients connect with leading medical research.
View 16 trials in Seattle
Filter (16)

Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)

Sanofi Clinic, Mill Creek + 3 more

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 \[RIVER-AD\]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 \[RIVER-AD\] study).Show More

Verified

Recruiting
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team

Nemolizumab for Eczema

Galderma Clinic, Seattle + 1 more

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team

Upadacitinib + Topical Corticosteroids for Eczema

AbbVie Clinic, Seattle + 1 more

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director

Rocatinlimab for Eczema

Amgen Clinic, Mill Creek + 1 more

This trial is testing a new medication called rocatinlimab to see if it works well and is safe when used alone. It targets patients who might benefit from a new treatment option.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
MD
Study Director

Abrocitinib for Atopic Dermatitis/Eczema

Pfizer Clinic, Seattle + 6 more

This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Pfizer CT.gov Call Center
Study Director

Lebrikizumab for Eczema

Eli Lilly Clinic, Seattle + 2 more

This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Rocatinlimab for Atopic Dermatitis

Amgen Clinic, Bellevue + 1 more

This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director

Povorcitinib for Prurigo Nodularis

Incyte Clinic, Mill Creek + 2 more

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 5 - 8 Weeks
Incyte Medical Monitor
Study Director

Povorcitinib for Prurigo Nodularis

Incyte Clinic, Seattle + 1 more

The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Recruiting
Phase 3
Est. 4 - 6 Weeks
Incyte Medical Monitor
Study Director

Ruxolitinib Cream for Eczema

Incyte Clinic, Mill Creek + 1 more

This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Incyte Medical Monitor
Study Director
Page 1 of 2

Frequently Asked Questions

How much do eczema clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do eczema clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across eczema trials in Seattle, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for eczema patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Seattle is research being conducted for eczema?

The list does not include any prominent hospitals or neighborhoods in Seattle conducting clinical trials for eczema.

What promising new drugs are being tested?

In Seattle, eczema research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Dupilumab, Tralokinumab, and Upadacitinib.